JP2004505087A5 - - Google Patents

Download PDF

Info

Publication number
JP2004505087A5
JP2004505087A5 JP2002515900A JP2002515900A JP2004505087A5 JP 2004505087 A5 JP2004505087 A5 JP 2004505087A5 JP 2002515900 A JP2002515900 A JP 2002515900A JP 2002515900 A JP2002515900 A JP 2002515900A JP 2004505087 A5 JP2004505087 A5 JP 2004505087A5
Authority
JP
Japan
Prior art keywords
slurry
give
solution
ethyl
ethyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002515900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505087A (ja
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed filed Critical
Priority claimed from PCT/IB2001/001280 external-priority patent/WO2002010171A1/en
Publication of JP2004505087A publication Critical patent/JP2004505087A/ja
Publication of JP2004505087A5 publication Critical patent/JP2004505087A5/ja
Pending legal-status Critical Current

Links

JP2002515900A 2000-07-28 2001-07-18 結晶性治療剤 Pending JP2004505087A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (2)

Publication Number Publication Date
JP2004505087A JP2004505087A (ja) 2004-02-19
JP2004505087A5 true JP2004505087A5 (cg-RX-API-DMAC7.html) 2007-11-08

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002515900A Pending JP2004505087A (ja) 2000-07-28 2001-07-18 結晶性治療剤

Country Status (45)

Country Link
EP (1) EP1305314B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004505087A (cg-RX-API-DMAC7.html)
KR (1) KR100457937B1 (cg-RX-API-DMAC7.html)
CN (1) CN1207297C (cg-RX-API-DMAC7.html)
AP (1) AP1400A (cg-RX-API-DMAC7.html)
AR (1) AR032628A1 (cg-RX-API-DMAC7.html)
AT (1) ATE286901T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001272690B2 (cg-RX-API-DMAC7.html)
BG (1) BG107266A (cg-RX-API-DMAC7.html)
BR (1) BR0112734A (cg-RX-API-DMAC7.html)
CA (1) CA2417264C (cg-RX-API-DMAC7.html)
CZ (1) CZ2003126A3 (cg-RX-API-DMAC7.html)
DE (1) DE60108398T2 (cg-RX-API-DMAC7.html)
DO (1) DOP2001000217A (cg-RX-API-DMAC7.html)
DZ (1) DZ3364A1 (cg-RX-API-DMAC7.html)
EA (1) EA004681B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP034454A (cg-RX-API-DMAC7.html)
EE (1) EE200300045A (cg-RX-API-DMAC7.html)
ES (1) ES2231521T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20053494B (cg-RX-API-DMAC7.html)
HR (1) HRP20030061A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0302982A3 (cg-RX-API-DMAC7.html)
IL (1) IL153226A0 (cg-RX-API-DMAC7.html)
IN (1) IN2002MU01649A (cg-RX-API-DMAC7.html)
IS (1) IS6626A (cg-RX-API-DMAC7.html)
MA (1) MA26931A1 (cg-RX-API-DMAC7.html)
MX (1) MX233602B (cg-RX-API-DMAC7.html)
MY (1) MY117831A (cg-RX-API-DMAC7.html)
NO (1) NO324220B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ523226A (cg-RX-API-DMAC7.html)
OA (1) OA12337A (cg-RX-API-DMAC7.html)
PA (1) PA8523501A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020277A1 (cg-RX-API-DMAC7.html)
PH (1) PH12001001922B1 (cg-RX-API-DMAC7.html)
PL (1) PL365133A1 (cg-RX-API-DMAC7.html)
PT (1) PT1305314E (cg-RX-API-DMAC7.html)
SK (1) SK572003A3 (cg-RX-API-DMAC7.html)
SV (1) SV2001000570A (cg-RX-API-DMAC7.html)
TN (1) TNSN01112A1 (cg-RX-API-DMAC7.html)
TW (1) TWI285643B (cg-RX-API-DMAC7.html)
UA (1) UA72631C2 (cg-RX-API-DMAC7.html)
UY (1) UY26854A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002010171A1 (cg-RX-API-DMAC7.html)
YU (1) YU4703A (cg-RX-API-DMAC7.html)
ZA (1) ZA200301457B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
KR100824193B1 (ko) 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-d]피리미딘
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0509731A (pt) 2004-04-07 2007-09-25 Pfizer pirazol[4,3-d]pirimidinas
PL1881985T3 (pl) 2005-05-12 2011-05-31 Pfizer Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE299503T1 (de) * 1998-04-20 2005-07-15 Pfizer Pyridin-3-carbonsäurederivate und ihre verwendung als zwischenprodukte
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Similar Documents

Publication Publication Date Title
JP2008510770A5 (cg-RX-API-DMAC7.html)
JP2010521514A5 (cg-RX-API-DMAC7.html)
JP2007520453A5 (cg-RX-API-DMAC7.html)
JP2006526031A5 (cg-RX-API-DMAC7.html)
JP2008518890A5 (cg-RX-API-DMAC7.html)
JP2007514638A5 (cg-RX-API-DMAC7.html)
JP2005516064A5 (cg-RX-API-DMAC7.html)
JP2004505087A5 (cg-RX-API-DMAC7.html)
WO2004020438A2 (en) Novel processes and intermediates for preparing triazolo-pyridines
JPWO2021220648A5 (cg-RX-API-DMAC7.html)
JP2016531925A (ja) ペメトレキセド製造のための中間体製造方法及びこれを用いて高純度ペメトレキセドを製造する方法
CN104557938B (zh) 一类N‑取代吡唑并[3,4‑d]嘧啶酮类化合物及其应用
US20100305318A1 (en) Process for the Manufacture of Anagrelide Hydrochloride Monohydrate
JP2003234133A5 (cg-RX-API-DMAC7.html)
CA2425561A1 (en) Process to prepare 1,4-dihydropyridine intermediates and derivatives thereof
CN103483261A (zh) 1-取代苯基-3-羧甲基-5-吡唑啉酮的制备方法
JP2001089467A (ja) 新規ヒドロキシクマリン誘導体及びその製造方法
CN101522680A (zh) 制备阿巴卡韦的方法
CN102796036A (zh) 一种阿托伐他汀钙的制备方法
HRP20161186T1 (hr) Soli heterociklamidno supstituiranih imidazola sa sulfonskim kiselinama
CN1115338C (zh) 4-[(2′,5′-二氨基-6′-卤代嘧啶-4′-基)氨基]-环戊-2-烯基甲醇的制备方法
CN100532389C (zh) 改进的2-取代腺苷的合成
CA2366521A1 (en) A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
JP2001522825A5 (cg-RX-API-DMAC7.html)
RU2069660C1 (ru) Способ получения производных 4-аминопиридина